Quercetin failed to move blood sugar, insulin resistance or HbA1c in pooled trials

Quercetin is a flavonoid found in everyday plant foods and has become a popular supplement, with claims spanning inflammation, immunity and blood sugar control. People with metabolic syndrome, the cluster of raised glucose, unfavourable blood fats and related disorders, are precisely the audience such claims target. Individual trials of quercetin on glycaemic measures have come to different answers, which leaves buyers with no clear picture. This review pooled the randomised evidence to settle whether the supplement genuinely moves fasting glucose, insulin resistance or longer-term blood sugar.

The authors searched PubMed, MEDLINE, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials up to 30 August 2018 for randomised controlled trials of quercetin supplementation in people with metabolic syndrome and related disorders. Out of 357 reports screened, nine studies providing 10 effect sizes qualified for the analysis. The pooled outcomes were fasting plasma glucose, insulin resistance estimated by the HOMA model, haemoglobin A1c and insulin concentrations, with subgroup breakdowns by trial duration, dose and participant age.

Pooled across all trials, quercetin supplementation did not affect fasting plasma glucose, insulin resistance or HbA1c. The subgroups told a more nuanced story. Fasting glucose fell significantly in trials lasting 8 weeks or longer and in those using doses of 500 mg per day or more. Insulin concentrations dropped in trials that enrolled people younger than 45 and in those using at least 500 mg per day. The headline, though, remains the overall null across every primary glycaemic measure.

This pooling tempers the enthusiasm generated by individual positive trials: on the primary question, quercetin moved no glycaemic marker. The subgroup findings hint that dose and duration thresholds might matter, a common pattern with plant compounds, but subgroup results are weaker evidence and better read as hypotheses for future trials than as conclusions. Whether a sustained higher-dose regimen genuinely improves glycaemic control, and whether any such change lasts or affects outcomes that matter, are the questions this review leaves open.

If quercetin is in your supplement stack for blood sugar reasons, this is a reason to lower expectations: across the pooled trials it changed none of the main glycaemic measures. The only signals appeared with at least 500 mg per day or trials of 8 weeks or more, and those come from subgroup analyses that deserve caution rather than confidence. For anyone weighing the cost of another capsule, the honest summary is that the strongest available analysis found no overall effect.